Abstract: Protein-protein interactions (PPIs) can be useful targets for different pathologies. In fact controlling a function or attempting to repair an anomaly often means interfering with the cross-talk among different proteins.
INTRODUCTION
Although medical research was started a long time ago, still today, the discovery of new molecules often happens by serendipity.
To favor a major rationalization of the scientific research, it would be desirable to organize the enormous amount of available data and information, which is otherwise merely registered.
As in a city map where roads are not only listed, but are connected together giving a higher degree of information, in molecular interactions maps (MIMs) the detailed knowledge of different elements within the cell are not simply cited but interrelated to each other.
Results from recent years indicate that there is a huge number of proteins whose function is to modulate various aspects of cell signaling. The cell can therefore be studied as a network of interconnected signaling pathways, which integrate signals from a variety of extracellular and intracellular sources. Biochemical networks, including those containing signaling pathways, display a wide range of regulatory properties. The mechanisms underlying these complicated behaviors involve many interacting components and cannot be understood by isolated experiments but need to be integrated and organized using models, which can provide a new overview of this complexity.
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Understanding the signaling network of a cell can suggest new interpretations or questions to improve the knowledge on possible therapeutic molecules and can make the formulation of new experimental procedures easier. In order to explore the signaling network of a cell appropriate knowledge environments, known MIMs, are used. They provide a way to organize and integrate the known interactions among molecular species in the form of diagrams, maps and/or databases. This diagrammatic language has been proposed for the first time by Dr Kurt Kohn in 1999 [1, 2] . With all this instant information it is possible to focus the attention only on key proteins/molecules of the signaling network of the cell, which appear to be interesting targets for an aimed therapeutic research.
The choice of the type of substances with which to start a project can depends on the target. If a rational research is performed, a first approach with drug-like molecules seems convenient for enzymes and conventional receptors with defined active sites or pockets (recall the experience of Gleevec, organic molecule competitor of ATP, selective inhibitor of Bcr-Abl in Chronic Myeloid Leukemia), but it can be less obvious in the case of a typical protein-protein interaction.
In the first phase of a project, an intuitive way to interfere with a protein-protein interaction can be to use a protein entity. Proteins are very complex molecules, but, considering that binding sites with other macromolecules are made by a shorter number of amino acids, they can be reproduced by means of peptide fragments, which maintain protein character, but are conveniently smaller. In a second phase, lead peptides can advantageously be transformed into peptidomimetics and drug-like molecules.
MOLECULAR INTERACTION MAP, A USEFUL TOOL TO STUDY THE NETWORK AROUND A TARGET PROTEIN: OUR EXPERIENCE WITH C-MYC
The complexity of the molecular interactions implicated in cell regulatory networks challenge the human comprehension. Since a cell is directed by proteins, trying to collect all possible information requires an appropriate "knowledge environment".
Most PPIs involve more than a single pair of proteins. In some cases, as many as 50 proteins interact as part of a large, multimeric protein complex. It is almost deliberately naive to think that inhibiting a single interaction will not have multiple effects, including counterproductive effects on other pathways. Thus, choosing a tractable target that actually has the desired biological effect poses indeed a major challenge: the design of a SMPPII (small molecule protein-protein interaction inhibitor). To some extent, only animal experiments and clinical trials will test the field's capacity to overcome this hurdle, but protein-protein interaction maps provide a way to maximize the odds.
The goal of producing a protein interaction map is to find new drug targets. Ideally, with a map that has been crossvalidated with good data, chosen targets are both tractable (i.e., capable of being inhibited) and smart. For example, if one sought to block the interaction between two proteins, A and B, it would be helpful to know how A and B interact with other neighbouring proteins as well, so that the drug candidate does not also inadvertently block the interaction of A with other protein C or D or E.
For this reason, we decided to study the c-Myc signaling network with the help of Molecular Interaction Maps (MIMs) [1, 2, 3] .
It is obviously rather difficult to keep in mind all of the known interactions that may be pertinent to a particular experimental or theoretical question, and a MIM can be used in much the same way as a road map or electronic circuit diagram. MIMs can suggest new interpretations or questions for experiments. The act of preparing a MIM imposes a discipline of logic and critique to the formulation of functional models. Finally, the diagram convention provides shorthand for recording complicated findings or hypotheses. There is of course a difficulty in preparing useful maps, because of the incompleteness and uncertainty of knowledge, as well as the limited scope of applicability of some interactions. An important aspect of MIMs is that they are always linked to an annotation list that summarizes current information relevant to particular interactions and provides references. All molecular species are also listed in a glossary (see Table 1 ), which provides brief descriptions of the molecules depicted in the maps. The maps can therefore function as a review and could be updated interactively via the Internet providing a current summary of an area.
To depict a MIM we use a graphic program called Canvas, but any other drawing program can be used. The main symbols are listed in Fig. (1) .
We present here a Molecular Interaction Map which depicts molecular interactions operating in the control of the mammalian cell cycle in a concise and reasonably complete description. It should be noted that the map depicts molecular interactions per se, and does not indicate biological behavior in any particular cell type or cell state. It shows only what the molecules "see"; the molecules do not "know" their functional purpose. Thus a depicted interaction may occur whenever the relevant molecules meet. Insights into biological function should emerge once we have enough information about molecular interactions.
At the molecular level c-Myc appears to regulate cell cycle progression by promoting coordinate changes in expression of a large number of genes [4] [5] [6] [7] [8] [9] (see also www.myccancergene.org). Deregulated myc expression leads to direct or indirect activation of cyclin D1, D2, E and A, as well as cdk4 and Cdc25A. c-Myc also suppresses cell check-point genes such as gadd45 and gadd153, as well as cyclin kinase inhibitors p15 INK4b , p21
Cip1 and p27 Kip1 , via inhibition of the transcription factor Miz1 [4, 7] . The cascade triggered by c-Myc is unique at a molecular level and yet has features that functionally overlap with other cell cycle regulators such as Ras (a cytoplasmic network switchmediator) and E2F (another family of transcription factors). Indeed, one of the roles of c-Myc is to activate G1 cyclin/cdk complexes and subsequently to inactivate the restriction point characterized by the product of the retinoblastoma gene, pRb [10, 11] . This is further supported by observations that c-Myc can stimulate the expression of the Id2 protein that inhibits pRb function [12] . In addition, c-Myc induces E2F-1 and E2F-2, which in turn regulate an independent, parallel pathway, that plays an important synergistic role with c-Myc in cell cycle control [11, 13] . The E2F family regulates many target genes, including those required for replication and mitotic activities. c-Myc seems therefore to coordinate the molecular events required for the cell to traverse G1 to S phase by regulating both D and E cdk/cyclin complexes as well as the E2F transcription factors and their downstream cascades.
The following Fig. (1) reports cell cycle control via cMyc and Max. c-Myc is negatively regulated by GSK3β (and perhaps other kinases), which phosphorylate c-Myc and β-catenin, thereby tagging both proteins for degradation. Since β-catenin stimulates the transcription of c-Myc, the two kinase actions down-regulate c-Myc by different routes, an example of coherent action (see interactions #27-31).
The activities of c-Myc favoring cell growth consist of both positive effects on transcription of some genes, and negative effects on transcription of others (coord. 6F-G). At top-center of Fig.(1) , a group of genes positively regulated by c-Myc:Max is shown (coord. 3A-5B). At top-right of the Map a group of genes for which c-Myc:Max inhibits transcription is also shown (coord. 6A-7B ). There is a logic coordination between the two types of effects, both favoring entry into S phase.
Cells of most normal tissues can enter a state of prolonged quiescence (G0). In G0, a distinct multi-protein complex confers prolonged silencing to genes that are regulated by both E2F6:DP and Mga:Max (see interactions #20-22). 
Abbreviation Definition Coordinates
Myc (c-Myc) a multifunctional protein that can regulate cell cycle, cell growth, differentiation, apoptosis, transformation, genomic instability and angiogenesis. Deregulation of the cellular c-myc protooncogene is one of the strongest activators of carcinogenesis
3-4D
ODC (ornithine decarboxylase), the rate-controlling enzyme for polyamine biosynthesis; essential for progression through S-phase 3A Max appears to be a fulcrum for the regulation of c-Mycdependent genes during the cell cycle. Max is a long-life protein, capable of forming transcription-inhibitory, as well as transcription-stimulatory complexes (see interaction #14-16). These stimulatory and inhibitory effects work coherently to regulate transcription of important genes during cell cycle progression.
It is well known, as cited above, that c-Myc can activate transcription with many other molecular components. Merika and Thanos named this complex enhanceosome [14] . This dynamic high order structure seems to be required around a transcription factor like c-Myc in order to be able to call in the RNA-polymerase II complex and start the transcription of downstream genes. Many modular proteins participate and cooperate to allow access to the DNA chromatin for the cMyc:Max heterodimer. As it can be seen from the map this set of proteins includes an acetyltransferase subcomplex for the acetylation of histones and destabilization of other proteins of chromatin (HAT complex), a SWI/SNF complex for phosphorylation of histones and bridge proteins (PTEFb complex) between the enhanceosome and the RNA Polymerase II complex (see interaction #6-9). As it is also possible to see in the map, trying to dismount this complex can provide a way to stop c-Myc transcriptional activity especially when it is deregulated, as is the case in many tumors.
MOLECULAR INTERACTION MAP ANNOTATIONS
• #1-2, coord. 4D-E: c-Myc binds Max (#1), and this interaction is required for their binding to sequence-specific sites on DNA (#2). Interaction between c-Myc and Max requires the bHLH-LZ domains. Max can homodimerize, at least in vitro (not shown), although this has been difficult to detect in cells [4] .
• #3, coord. 4E: The c-Myc:INI1 interaction was observed in vitro and in vivo. c-Myc binds INI1 with its helix-loop-helix and leucine zipper domain at its carboxylterminal region. The c-Myc:INI1 interaction helps recruiting the SWI/SNF complex [15] .
• #4, coord. 2E: TRRAP associates in vivo with c-Myc and this association is necessary for recruiting the HAT complex [16] .
• #5, coord. 3E: c-Myc binds cyclinT1 (cycT1) structurally and functionally [17] . CyclinT1 paired with Cdk9 forms the human P-TEFb complex [18] .
• #6-9, coord. 3E-4F: c-Myc:Max can recruit different complexes onto DNA, such as SWI/SNF complex, HAT complex and P-TEFb complex. These complexes are required for chromatin remodeling, which makes chromatin competent for transcription. c-Myc binds SWI/SNF by way of the INI1 component of SWI/SNF [15] . SWI/SNF contains at least a DNA-dependent ATPase like BRG1 or hBRM (#6), which are capable of remodeling arrays of nucleosomes in ATP-dependent fashion, leading to "loosening" of the chromating structure and then allowing activation or repression of gene transcription [19, 20] . c-Myc binds the HAT complex (including histone acetyltrasferases GCN5) by way of TRRAP. GCN5 mediates the acetylation of histones, thereby activating transcription (#7) [21] . c-Myc interacts with the P-TEFb complex, which includes Cyclin T1:Cdk9, a kinase that phosphorylates the RNAP II C-terminal domain (#8) and facilitates promoter clearance and elongation (#9) [22] .
• #10-13, coord. 4E-4F: c-Myc can bind a variety of proteins which enhance (e.g. AMY-1 or Pam #10, 12) or suppress (e.g. BIN1, cdr2 or MM1 #11, 13) its transcriptional activity [8] .
• #14-16, coord. 5D: Mad-family proteins (including Mad, Mad3, Mad4, and Mxi1), Mnt, and Mga, bind Max competitively with c-Myc (#14). All of these complexes can bind the same consensus sequence as c-Myc:Max (#15-16), but do not activate transcription [23] .
• #17-19, coord. 5D-6E: Mad:Max heterodimers bind Sin3A/B proteins (#17) and recruit HDAC to the promoter of target c-Myc genes (#18). HDAC removes acetyl groups on the amino-terminal lysine residues of core nucleosomal histones and thereby blocks transcription (#19) [8] .
• #20-22, coor. 5-6D: Mga:Max complex binds E2F6:DP1,2 (#20) and then recruits chromatin modifiers such as HTM, HP1γ and PcG proteins (#21). This complex methylates nucleosomes and contributes to the propagation of inactive chromatin (#22) [24] .
• #23-26, coord. 3D: c-Myc can be phosphorylated at Thr-58, Ser-62, and/or Ser-71 by a number of kinases, including GSK3β (#24). Phosphorylation of Thr-58, which requires prior Ser-62 phosphorylation (#25), promotes c-Myc degradation (#26) through the ubiquitin/proteasome pathway [25] .
• #27-28, coord. 3C: GSK3β can also phosphorylate and tag for degradation other proteins, including β-catenin and Cyclin D (not shown).
• #29-31, coord. 2C-D: β-catenin binds the trascriptional factor TCF:LEF (#29) and thereby activates transcription of the c-Myc gene (#30,31) [26] .
• #32-38, coord. 1A-2B: c-Myc can also be regulated through the TGFβ pathway. TGFβ binds TGFβR-II on the cell surface (#32,33), leading to recruitment (#34) and phosphorylation of TGFβR-I (#35). Phosphorylation of TGFβR-I activates its catalytic domain, which can phosphorylate specific sequences on Smad3 (#36). Phosphorylation of Smad3 is required for binding to Smad4 (#37,38) and for transport of the Smad3:Smad4 complex into the nucleus [27] .
• #39-43: Smad3:Smad4 binds and activates the c-Myc promoter (#39, coord. 2C). When Smad3:Smad4 is on the promoter, E2F4,5:DP1,2 can bind to an adjacent site (#40-41, coord. 2C-D) . E2F4,5:DP1,2 can then recruit p107 (#42, coord. 4B) and thereby inhibit the promoter (#43, coord. 3C) [27] .
• #44, coord. 6F: Many genes are activated by cMyc:Max heterodimers. Many of these genes participate in the control of cell proliferation. c-Myc:Max plays an essential role in stimulating cell proliferation, particularly in the G1/S transition ("restriction point"), and can push cells through the G1/S checkpoint [7] .
• #45, coord. 3B: c-Myc recognition elements are present in the promoters of genes coding for E2F1-3 [28] .
• #46-48, coord. 5C: E2F1-6 can bind DP1 or 2 (#46). E2F1-5:DP heterodimers can stimulate transcription of genes required for S-phase (#47), including c-myc (see #40,41 above). E2F6:DP heterodimers bind to promoters in competition with the other E2F:DP complexes and inhibit transcription in a dominant-negative manner (#48) [29] . (E2F6:DP can function to inhibit c-Myc target genes -see #20-22 above)
• #49-50, coord. 5-6B: pRb binds and inhibits the transcription of E2F:DP target genes [29] .
• #51, coord. 4 -5B: Hyperphosphorylation of pRb abrogates the binding of pRb to E2F:DP heterodimers [29] .
• #52-53, coord. 3-4B: c-Myc stimulates the expression of Id2, an HLH protein that inhibits pRb function and thus promotes S phase [23] .
• #54-55, coord. 3-5B: c-Myc stimulates the expression of Cul1, a component of the ubiquitin ligase SCF(Skp2) (not shown) which targets p27 kip1 for degradation (see #75 below). C-Myc-induced Cul1 expression matches well with the kinetics of declining p27 kip1 protein [30] .
• #56-57, coord. 3-4A: c-Myc stimulates the expression of Cdc25A, a dual specificity phosphatase that stimulates the kinase activities of Cyclin D:Cdk4/6 and Cyclin E:Cdk2 [23, 31] .
• #58-59, coord. 3A: c-Myc stimulates the expression of ODC and CAD, enzymes required for DNA replication [8, 32] . c-Myc also stimulates the expression of Ctd1, which functions to initiate replicons [29] .
• #60-61, coord. 3A: c-Myc stimulates the expression of RCC1, which promotes cell proliferation, especially the G2-M transition [8] .
• #62-64, coord. 4-5A: Cyclin D1,2 and Cdk4 are direct transcription targets of the c-Myc/Max/Mad network [8] . CycD:Cdk4 promotes S phase by phosphorylating pRb at a subset of sites and also by sequestering p27 kip1 away from CycE:Cdk2 [23] .
• #65-66, coord. 5A-6B: CycE:Cdk2 phosphorylates pRb at additional sites, and could also phosphorylate p27 kip1 [33, 34] .
• #67, coord. 6G: c-Myc can repress several genes (see #68-77 and 83 below), repressing a discrete number of transcription factors.
• #68-69, coord. 6-7A: The transcription of p15 ink4b is stimulated by TGFβ (not shown) and repressed by c-Myc [23] . p15 ink4b inhibits CycD:Cdk4/6 (but not CycE:Cdk2).
• #70, coord. 7D: Several proteins repressed by c-Myc inhibit the G1/S transition, including p15 ink4b , p21 cip1 , p27 kip1 and Gas1 [13, 23, 35] .
• #71-72, coord. 6-7A: p21 cip1 is repressed by c-Myc. p21 cip1 binds and inhibits Cyclin E:Cdk2 and Cyclin A:Cdk2 [36] . Another way that c-Myc may stimulate cell cycle progression is by releasing Cdk2 from the complex with p21 cip1 [37] (not shown).
• #73-75, coord. 6-7B: p27 kip1 binds and inhibits Cyclin:Cdk complexes [29] . p27 kip1 is first sequestered by cMyc-induced Cyclin D2 (not shown) and subsequently degraded (#75) in response to CyclinE:Cdk2-dependent phosphorylation (see #66) by a ubiquitin/proteasome dependent pathway [23] .
• #76, coord. 7B: c-Myc transcriptionally represses the expression of a growth arrest gene, gas1. A conserved Myc structure, Myc Box II (MBII), is required for repression of gas1 [34] . Gas1 is a membrane-associated protein that blocks the G0/S transition of quiescent fibroblasts when ectopically expressed [38] .
• #77-78, coord. 7B-C: Gadd45 is transcriptionally activated by p53 and repressed by c-Myc in an indirect manner [23] . Gadd45 inhibits the G2/M transition (#78). The gadd45 gene is induced by a variety of genotoxic agents, e.g. methylmethane sulfonate, UV radiation, hydroxyurea, and ionizing radiation. Induction of gadd45 by ionizing radiation is regulated transcriptionally by p53 via a p53-binding site in the third intron of gadd45. With DNA base-damaging agents, p53 is not required for gadd45 induction but p53 can contribute to its activity [36] .
• #79-81: Miz-1 is a transcription factor that synergizes with Smad3:Smad4 (#79, coord. 1C); the resulting complex of transcription factors may function jointly to activate inhibitors of G1/S transition genes, among them p15 ink4b (#80-81, coord. 2-4G) [39] .
• #82-83: c-Myc:Max binds Miz-1 (#82, coord. 1D) (as well as other transcription factors, such as YY1 and CBF-C/NF-Y (not shown)); c-Myc:Max may thus be recruited to promoters bearing Miz-1 and Smad3:Smad4. c-Myc:Max binding inhibits these transcription factors (#83, coord. 3G). c-Myc itself seems to interfere with the transcriptional function of Miz-1 by preventing recruitment of the coactivator p300 (not shown) [40] .
THE C-MYC PROTEIN IN CANCER
The c-myc gene is one of the most widely studied oncogenes. A large number of human tumors with overexpression of c-Myc and/or with genetic alterations at the myc locus have been described. Deregulation/overexpression of c-Myc is present in the majority of colon cancers and small-cell lung cancers [41, 42] . The gene product of c-myc is a nuclear phosphoprotein 439 or 454 amino acids long. Numerous studies have confirmed that cMyc (in cooperation with other signaling proteins) promotes cell cycle progression through G1 into S phase, which leads to an increase of the cell mass [43] . We try to interfere with c-Myc activity through the synthesis of peptidomimetic molecules that could work as a wedge between the c-Myc/Max heterodimer and a crosstalking protein: INI1 (integrase interactor-1) is a possible candidate, as explained hereafter.
Here we have an example of protein-protein interaction that must be inhibited: Myc and INI1. Studying the zone of interaction of c-Myc we took inspiration from Helix 1 (H1) of c-Myc and a more stable analogue of H1 linked to the internalization sequence derived from the III alpha-helix of Antennapedia (Int) [45] was synthesized. The resulting peptide (L-Int-H1-S6A,F8A, sequence: RQIKIWFQNRRM KWKKNELKRAFAALRDQI) showed antiproliferative activity towards the mammary cancer line MCF7 and the colon cancer line HCT116. The retroinverse form (RI-Int-H1-S6A,F8A) was synthesized and a 5-10 fold high activity and 30-35 fold superior stability was achieved [46] .
In order to understand which side chains are essential for biological activity, an ala-scan mapping of the retroinverse H1 motif was carried out: Lys in 4 and Arg in 5 turned out to be necessary, because the activity of related peptides without these side-chains was strongly reduced in comparison with the reference RI-Int-H1-S6A,F8A activity. These basic amino acids in the c-Myc Helix1 structure project towards the outside of the hetero-dimer and are presumably involved, maybe together with some loop residues and helix basic sidechains, in interactions with a third protein.
In the literature [15] it is reported that the part of c-Myc known as basic-helix1-loop-helix2 binds INI1 between amino acids 181 and 240 (of INI1): our peptidomimetic molecules, mimicking helix 1 of c-Myc, could interact with the same domain of INI1.
In the region of INI1 (amino acids: 181-240) that interacts with c-Myc, there is a high density of acidic residues, such as Glu and Asp. It is not unlikely that there could be an interaction between some of these acidic sidechains and the basic side-chains of c-Myc, including the mentioned adjacent Lys 4 and Arg 5 of the H1 motif.
From this point of view, our inhibitor is an antagonist of c-Myc for the receptor INI1, avoiding c-Myc interaction.
The inhibitor binds INI1 but does not induce the same action as c-Myc.
Our type of retro-inverse peptidomimetic molecule made of D-amino acids appears very stable in cell cultures in vitro. Injected i.v. in mice, it seems capable of reaching high concentrations in important organs like liver, lung, spleen and kidney, but is almost undetectable in the brain [47] .
PEPTIDES AS INHIBITORS OF PROTEIN-PROTEIN INTERACTIONS
Peptides can be a good starting point to discover new PPIs modulators and sometimes can also be useful drugs. Here are some examples of peptides active against cancerous and viral pathologies, derived from sequences involved in PPIs.
We know that Protein kinases are important drug targets in oncologic, immunologic, and metabolic disorders. The common strategy which has led to the development of drugs in this field, such as Glivec and Iressa, is to target the ATP binding site of the enzyme [48, 49, 50 ].
An original study presents a different approach based upon deriving short peptides from specific regions in the catalytic domain of the kinase that are implicated in kinasesubstrate interactions, namely the HJ-αG and αD domains (regions X-XI and V, respectively), specific accessible and variable regions for PPIs. The derived peptides mimic regions of the kinase and therefore compete with the kinase for binding to the substrate (or to other modulators of the kinase), and subsequently abrogate the kinase-dependent signaling. To enable permeation of peptides into cells myristoylation is adopted.
A peculiarity of this method is that the regions from which the inhibitory peptides are derived share conserved structural patterns in all kinases, suggesting a general approach for generating inhibitors of kinase-dependent signaling, applicable to any kinase. Short myristoylated peptides are derived from the target regions of the tyrosine kinases c-Kit and Lyn and the serine/threonine kinases 3-phosphoinositide-dependent kinase-1 (PDK1) and Akt/protein kinase B (PKB).
For each kinase, an active designed peptide was shown to selectively inhibit the signaling of the kinase from which it was derived, and to inhibit cancer cell proliferation in the micromolar range. The most potent peptide inhibitor could be developed further into a drug candidate and could also complement the ATP-targeted approach in cases of ATPmimic resistant mutants [51] .
An example of transformation of a peptide inhibitor into a more stable molecule is that regarding MDM2. MDM2 binds the transcription factor p53 inducing its degradation. Overexpression of MDM2 has been observed in many tumors and it has also been shown that p53 function can be restored by disrupting its interaction with MDM2. Studying the zone of interaction of p53 with MDM2, a 15-mer peptide was synthesized presenting the critical residues Phe, Trp and Leu necessary for the interaction with MDM2. The first peptide was an L-peptide degradable by peptidases. In order to avoid its degradation, D-amino acids were used and an inverse peptide (same sequence, but D-amino acids) and a retroinverse peptide (inverted sequence, D-amino acids) were built. The retroinverse isomer of the natural p53 peptide inhibited MDM2-p53 interaction with a potency comparable to that of the initial peptide, whereas the binding of the inverse peptide was not detectable, because only the retroinverse and not the inverse peptide presented the same spatial disposition of side-chains, in other words was superimposable with the natural peptide [52] .
A downstream target of p53 is p21 WAF1 , that mediates growth suppression. The primary function of the p21 WAF1 protein appears to be the inhibition of G1 cyclin-Cdk complexes. Thus, if the region(s) of p21
WAF1 that contain its inhibitory activity is(are) identified, it is possible to provide a template from which to develop novel antiproliferative drugs for use in tumours with a defective p53 pathway.
Small synthetic peptides, composed of amino-acids 141-160 of p21 WAF1 bind to and inhibit cyclin D1-Cdk4, with an I 0.5 of 0.1 µM, and cause cycling cells to arrest at the G1/S-phase boundary. They are endowed with growth inhibition activity in vivo [53] .
Another cancer target is constituted by proteins involved in apoptosis. IAPs (Inhibitors-of-Apoptosis Proteins) and in particular XIAP are up-regulated in many cancers. The proapoptotic protein Smac binds to IAPs, thereby releasing caspases and re-activating apoptosis. A 4-mer peptide derived from Smac also binds to XIAP with ~500nM affinity [54] .
On the other hand, peptides capable of selectively disrupting PPIs that are required for viral replication represent potential agents for antiviral therapy. One of the first examples of viral product that could be inhibited by the peptide YAGAVVNDL, targeted to the functional interaction between subunits, is the ribonucleotide reductase of herpes simplex virus [55] . So a new class of antiviral compounds has been studied for its potential utility as inhibitors of herpes simplex virus (HSV) replication. These compounds prevent association of the two subunits of HSV ribonucleotide reductase (RR), an enzyme that catalyzes the conversion of ribonucleotide diphosphates into the corresponding deoxyribonucleotides, thereby preparing the DNA building blocks required for HSV genomic replication. These inhibitors are based on the C-terminal amino acid sequence of the HSV RR small subunit (R2), VVNDL, which bind to the RR large subunit (R1) and permits subunit association and subsequent catalytic activity. The inhibitors, which mimic this C-terminal sequence, but are modified to enhance stability, competing with R2 for binding to R1, show antiviral activity in vivo, suppress the replication of HSV-1, HSV-2 and acyclovir-resistant HSV strains in cell culture, and also strongly potentiate the antiviral activity of acyclovir [56] [57] [58] [59] .
Known inhibitors of protein-protein interactions are either designed peptides derived from the sequence of one of the dimerization partners or small organic molecules found in specific screens. For example, HIV protease is catalytically active only as a homodimer and can be inhibited by breaking up the dimeric structure. A tetrapeptide (Ac-TLNF-COOH) derived from the carboxy-terminus of the protease inhibits the enzyme with a Ki of 45 µM through a dissociative mechanism. In fact, because the C-term plays an important role in linking the two monomers, the peptide, derived from the C-term sequence of the enzyme, binds to the inactive promoters and prevents their association into the active dimer [60] .
Fusion with the host-cell plasma membrane is a crucial stage in the life cycle of all enveloped viruses, because it is necessary to facilitate the intracellular deposition of the viral genome before replication. Trimeric class I virus fusion proteins undergo a series of conformational rearrangements that leads to the association of C-and N-terminal heptad repeat domains in a ''trimer-of-hairpins'' structure, facilitating the apposition of viral and cellular membranes during fusion. This final fusion hairpin structure is sustained by protein-protein interactions, resulting in a stable six-helix bundle, or trimer-of-hairpins.
Inhibition through targeting of the transient prehairpin intermediate can be accomplished in many viruses with synthetic HR-C (C-terminal heptad repeat region) peptide derivatives. For HIV, T-20 (Fuzeon, Enfuvirtide) was the first synthetic HR-C peptide derivative to be approved by the Food and Drug Administration for the treatment of HIV. It blocks cell fusion and viral entry at concentrations of less than 2ng/mL in vitro, and administered intravenously in monotherapy for 14 days is able to safe and successfully block viral entry in vivo [61, 62] .
Peptides were also chosen to inhibit HIV reverse transcriptase (RT). RT plays a key role in the replication of HIV by converting single-stranded genomic RNA into double-stranded proviral DNA, and represents one of the main targets for the development of AIDS therapies.
The biologically relevant and active form of human immunodeficiency virus reverse transcriptases (HIV-RT) found in infectious virions is a heterodimer containing two polypeptides, p66 and p51; the latter derived from the former by proteolytic cleavage of its C-terminal domain. Studying the dimmer interface by X-ray chrystallography, different peptides were synthesized and a short peptide (10 residues) corresponding to residues 395-404, was shown to block dimerization of reverse transcriptase in vitro and in infected cells. This peptide was highly efficient in abolishing the production of viral particles, without any adverse toxic side effects, when transduced into human immunodeficiency virus type 1-infected cells together with a peptide carrier. The sequence (KETWETWWTE) is well conserved in all isolates of HIV-1 and HIV-2 and is not reported in other proteins except reverse transcriptases, suggesting that such a peptide can be used as a highly specific inhibitor of HIV [63] .
Sometimes peptidomimetics are found to be active, but the right mechanism of action remains unknown. It is the case of NC37-37-15C, a potent peptoid inhibitor of HIV-1-LTR transcription in both primary T lymphocytes and transformed cell lines. The inhibitory effect of the compound, which is additive with azidothymidine (AZT), correlates with its ability to inhibit CTD (C-terminal domain of the RNA polymerase II) phosphorylation and shows a suitable profile for development of novel anti-HIV-1 drugs [64] .
Referring to HIV infection, additional targets, besides reverse transcriptase and HIV protease, could be the HIV proteins that centrally regulate viral gene expression. Tat is the main activator of viral gene expression and its interaction with the highly conserved TAR RNA element is a key point of its mechanism of action. Tat forms a 1:1 complex with TAR and the binding is mediated by a short, linear peptide domain of Tat that is predominantly composed of basic amino acids. This interaction may be considered a suitable target for the chemotherapy of HIV infection, because an inhibitor of the Tat/TAR interaction may have the potential to keep the virus in its dormant state. A basic peptoid oligomer of nine residues, CGP64222, can effectively compete with Tat for binding to TAR. NMR analysis showed that the stable compound binds directly to TAR RNA at the Tat-binding site. CGP64222 also exhibited inhibitory activity against HIV replication through interference with virus entry, blocking CXCR4 coreceptor binding [65] [66] [67] .
CONCLUSION
The relevant quantity of information that is generated day by day suggests that many pathologies derive from a deregulation of cross-talk between signaling proteins.
Interfering with one or another signaling protein means to be capable to understand the correct target for each alteration. In fact each protein does not act separately but is inside of a complex network of interactions.
The organization of the information currently available on PPIs, protein modifications, gene transcription controls, protein degradation and cell compartment translocation processes, in which our target proteins are directly or indirectly implicated, is the aim of Molecular Interaction Maps (MIMs).
More than 10,000 papers concerning c-Myc and c-Mycrelated proteins have been published. Even if we consider only 300 of them as potentially useful in terms of incremental knowledge at a biochemical/molecular level, this is an enormous amount of work (in the order of 20,000 months of research activity referred to an individual investigator, or about 50 full research lives in this specific field). It definitely seems reasonable to try to integrate this very large amount of biochemical/molecular details, in the search of a more general picture/meaning, and also in search of possible inspirations from the point of view of innovation at the level of finding lead molecules of pharmacological interest.
Taking c-Myc as an example, the network structure of the c-Myc-related controls on cell mass growth and cell proliferation can serve as a resource for the interpretation of functional data, formulation of hypotheses for experimental testing, and identification of molecular targets for therapeutic intervention. The interactions have been mapped, annotated, and referenced in a manner similar to that presented by K. W. Kohn in 1999 [1] .
A significant fraction of proteins that cross-talk directly with c-Myc is probably related to a higher order structure surrounding the c-Myc/Max heterodimer: the enhanceosome. To put a wedge between c-Myc and one of these directinteraction proteins is a strategy we already followed in our laboratory, in search of lead molecules of interest in terms of potential c-Myc inhibitors [47] .
It is important to underline that a MIM can give hints about dynamic events, but it is basically a static map of all known molecular interactions. A MIM describes a metasituation in a meta-cell, as if all the actors were present on the scene. A cinematographic description of events in a specific cell type is something we hope to become able to implement in the future, to allow an overview of the signaling network which could provide an idea of variation of protein concentrations, temporal sequences and lots of information that are still scanty in the literature.
What is also still difficult to achieve, in many cases, is to pinpoint the specific molecular pathology, at the level of signaling network, which makes a subset of a given type of cancer sensitive to the signaling-protein inhibitor drug, and other apparently similar subsets poorly sensitive.
Referring to examples cited above, peptides appear as a good starting point to discover new PPI modulators, and to be used as leads in the rational design of peptidomimetics. We usually think that peptides cannot be drugs because of their difficulty to enter the cell. This is not a rule: in fact peptides composed by a small number of amino acids naturally enter the cell and for higher peptides it is possible to use some tricks.
Several peptides have been demonstrated to be able to translocate across the plasma membrane of eukaryotic cells, often by energy-independent pathways. This is possible with protein-derived cell-penetrating peptides, rich in basic amino acids (Antennapedia-related peptides, TAT-derived peptides, basic artificial peptides or peptidomimetic molecules) [68, 45] and molecules with alternative internalization mechanisms (transportan, model amphipathic peptides, myristoylation, etc.) [69, 70] . D-Peptides analogs (made up of D-amino acids) can also be used. In particular, a D-analog of the III alpha-helix of Antennapedia was capable of efficient intracellular delivery of macromolecules with molecular weights 2-3 times greater than its own [46] . These molecules are endowed with high stability and high efficiency of internalization.
The identification of inhibitors of PPI has been accomplished by different approaches: modern technologies make it quite feasible to synthesize and test thousands of compounds each day, but obviously a structure based design, or better a sequence based design, is also suitable.
Interfering with proteinA-proteinB interaction or equally proteinA-receptor interaction means to make agonists or antagonists of the receptor keeping the proteinA as a model. It is possible to consider different types of molecules, but often in a first approach the best direct way is to isolate the sequence of proteinA responsible for the interaction and reproduce it, making a peptide. When a lead is obtained, peptidomimetic molecules, mimicking peptide spatial distribution of functional groups, can be reached in a more rational and fruitful way than testing thousands of compounds as a first screening.
The discovery process for obtaining peptide ligands that are more or less selective for a particular receptor (or acceptor) type or subtype, a specific antibody or antigen, a specific enzyme, and so on, has been greatly accelerated in recent years by the tremendous advances in synthetic peptide chemistry, combinatorial chemistry pioneered by peptide chemists, and the development of multiple, high-throughput binding and bioassay systems.
For the reasons discussed above, studying the zone responsible for the protein-protein interaction and understanding the amino acids involved in such interaction is a good and stimulating starting point to build interfering molecules.
Different reported peptides are endowed with activity against still incurable pathologies such as cancer and HIV and some of them are under clinical evaluation. These substances can be analogues of one amino acid such as Captopril or maintain a proteic structure such as Herceptin. The majority are composed of only a few amino acids.
